Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Merck
McKinsey
Express Scripts

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR SOTORASIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Sotorasib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04185883 ↗ Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Recruiting Amgen Phase 1/Phase 2 2019-12-17 To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
NCT04303780 ↗ Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). Active, not recruiting Amgen Phase 3 2020-06-04 A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
NCT04625647 ↗ Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Recruiting National Cancer Institute (NCI) Phase 2 2021-04-16 This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sotorasib

Condition Name

Condition Name for Sotorasib
Intervention Trials
Healthy Participants 7
Non-small Cell Lung Cancer 5
Non Small Cell Lung Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sotorasib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 11
Lung Neoplasms 9
Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sotorasib

Trials by Country

Trials by Country for Sotorasib
Location Trials
United States 112
Japan 23
Spain 12
Australia 5
Brazil 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sotorasib
Location Trials
Florida 6
Texas 6
California 5
New York 4
Maryland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sotorasib

Clinical Trial Phase

Clinical Trial Phase for Sotorasib
Clinical Trial Phase Trials
Phase 3 2
Phase 2 10
Phase 1/Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sotorasib
Clinical Trial Phase Trials
Not yet recruiting 12
Recruiting 9
Completed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sotorasib

Sponsor Name

Sponsor Name for Sotorasib
Sponsor Trials
Amgen 18
National Cancer Institute (NCI) 2
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sotorasib
Sponsor Trials
Industry 24
Other 18
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
Dow
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.